Literature DB >> 6499353

Combined alpha adrenoceptor antagonism and calcium channel blockade in normal subjects.

F Pasanisi, H L Elliott, P A Meredith, D R McSharry, J L Reid.   

Abstract

Because both verapamil and prazosin act on peripheral vascular smooth muscle and undergo extensive first-pass metabolism, the possibility of dynamic and kinetic interactions with their concurrent use was investigated. The acute hemodynamic effects of oral prazosin (1 mg), oral verapamil (160 mg), and their combination were evaluated in eight men with normotension. The kinetics of both drugs, alone and in combination, were also assessed. Verapamil did not change blood pressure or heart rate, but prazosin induced a fall in blood pressure, particularly on standing (lowest systolic pressure was 98 mm Hg). The combination of prazosin and verapamil had an earlier, longer, and greater hypotensive effect that was maximal 4 hr after dosing, with a standing systolic pressure of 89 mm Hg. Increases in heart rate were less after the combination (maximum of 102 bpm) than after prazosin alone (maximum of 112 bpm), although there were greater falls in blood pressure with the combination than with prazosin alone. Increases in plasma catecholamine and aldosterone levels and plasma renin activity were greatest with the combination. No differences were found in the kinetics of verapamil when combined with prazosin, but the combination affected prazosin kinetics, with increases in peak prazosin concentrations and AUC. Our data suggest that the greater hypotensive activity of the combination results at least in part from a kinetic interaction that enhances the bioavailability of prazosin, but it is possible that a dynamic interaction at the level of vascular smooth muscle or compensatory cardiac activity also plays a role.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6499353     DOI: 10.1038/clpt.1984.247

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  15 in total

Review 1.  Pharmacokinetic interactions with calcium channel antagonists (Part II).

Authors:  K D Schlanz; S A Myre; M B Bottorff
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

2.  Acute effects of felodipine and nifedipine on hepatic and forearm blood flow in healthy men.

Authors:  B Bengtsson-Hasselgren; O Rönn; L O Blychert; B Edgar; S Raner
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  A combination of verapamil, captopril, and diuretic in the treatment of severe hypertension.

Authors:  F Pasanisi; A L Ferrara; T Marotta
Journal:  Cardiovasc Drugs Ther       Date:  1988-07       Impact factor: 3.727

Review 4.  Calcium antagonists. Drug interactions of clinical significance.

Authors:  T Rosenthal; D Ezra
Journal:  Drug Saf       Date:  1995-09       Impact factor: 5.606

5.  The pharmacodynamics and pharmacokinetics of the combination of nifedipine and doxazosin.

Authors:  R Donnelly; H L Elliott; P A Meredith; C A Howie; J L Reid
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 6.  Concentration-effect analysis of antihypertensive drug response. Focus on calcium antagonists.

Authors:  R Donnelly; H L Elliott; P A Meredith
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

Review 7.  Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  D McTavish; E M Sorkin
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

8.  Verapamil pharmacokinetics and apparent hepatic and renal blood flow.

Authors:  P A Meredith; H L Elliott; F Pasanisi; A W Kelman; D J Sumner; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1985-08       Impact factor: 4.335

9.  The effect of oral verapamil therapy on antipyrine clearance.

Authors:  D O Rumiantsev; V K Piotrovskii; O S Riabokon; I D Slastnikova; E V Kokurina; V I Metelitsa
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

10.  Addition of chlorthalidone to slow-release nifedipine in the treatment of arterial hypertension: a controlled study versus placebo.

Authors:  L A Ferrara; T Marotta; F Pasanisi; P Mastranzo; M Mancini
Journal:  Cardiovasc Drugs Ther       Date:  1988-03       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.